Online citations, reference lists, and bibliographies.

The Third Italian Consensus Conference For Malignant Pleural Mesothelioma: State Of The Art And Recommendations.

S. Novello, C. Pinto, V. Torri, L. Porcu, M. Di Maio, M. Tiseo, G. Ceresoli, C. Magnani, S. Silvestri, A. Veltri, M. Papotti, G. Rossi, U. Ricardi, L. Trodella, F. Rea, F. Facciolo, A. Granieri, V. Zagonel, G. Scagliotti
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant Pleural Mesothelioma (MPM) remains a relevant public health issue, and asbestos exposure is the most relevant risk factor. The incidence has considerably and constantly increased over the past two decades in the industrialized countries and is expected to peak in 2020-2025. In Italy, a standardized-rate incidence in 2011 among men was 3.5 and 1.25 per 100,000 in men and women, respectively, and wide differences are noted among different geographic areas. The disease remains challenging in terms of diagnosis, staging and treatment and an optimal strategy has not yet been clearly defined. The Third Italian Multidisciplinary Consensus Conference on Malignant Pleural Mesothelioma was held in Bari (Italy) in January 30-31, 2015. This Consensus has provided updated recommendations on the MPM management for health institutions, clinicians and patients.
This paper references
10.1007/s10903-006-9024-8
Chernobyl Disaster Sequelae in Recent Immigrants to the United States from the former Soviet Union (FSU)
R. P. Foster (2006)
10.1016/S0167-8140(03)00229-9
Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey.
D. D. De Ruysscher (2003)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1016/j.cellsig.2009.12.007
Controlling of bone morphogenetic protein signaling.
Shan Zeng (2010)
10.1016/S0761-8417(05)84833-3
Mésothéliome malin de la plèvre. Rôle du chirurgien
D’après D. Grunenwald (2005)
10.1158/1538-7445.AM2015-CT103
Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
Evan W. Alley (2015)
[Malignant pleural mesothelioma. Role of surgery].
D. Grunenwald (2005)
10.1016/J.IJROBP.2007.02.047
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
A. Allen (2007)
10.1200/JCO.2013.54.8149
Developing a service model that integrates palliative care throughout cancer care: the time is now.
A. Partridge (2014)
guideline 2010 adults: British Thoracic Society pleural disease Investigation of a unilateral pleural effusion in
Clare Hooper (2010)
10.1097/PAS.0000000000000200
Well-differentiated Papillary Mesothelioma With Invasive Foci
A. Churg (2014)
10.1136/thoraxjnl-2013-204161
Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis
A. Reid (2014)
10.1136/bmj.39500.677199.AE
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
H. Schünemann (2008)
10.1080/10408440802273156
A Meta-Analysis of Asbestos-Related Cancer Risk That Addresses Fiber Size and Mineral Type
D. Berman (2008)
10.1023/A:1026300619747
Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends
F. Montanaro (2004)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1164/RCCM.200412-1731OC
Residential proximity to naturally occurring asbestos and mesothelioma risk in California.
X. Pan (2005)
10.5146/tjpath.2013.01210
The diagnosis of thoracic malignant mesothelioma: practical considerations and recent developments.
M. Smith (2014)
10.1136/oem.2009.047019
Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas
D. Mirabelli (2010)
10.1002/ajim.20844
Asbestosis and mesothelioma among British asbestos workers (1971-2005).
Anne-Helen Harding (2010)
Tumours of the pleura: mesothelial tumours
A Churg (2015)
10.4103/0971-3026.125577
Radiological review of pleural tumors
Binit Sureka (2013)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.1037/H0087153
The Tar Ponds kids: Toxic environments and adolescent well-being.
Johnna L. O'Leary (2002)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1136/jclinpath-2013-201609
Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA
D. Henderson (2013)
Una rara causa professionale di mesotelioma: meccanismi ed eziologia differenziale
Giuseppe Mastrangelo (2014)
10.1097/COC.0b013e3181d31f02
Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma
Carmine Pinto (2011)
10.1097/EDE.0b013e31826c3149
Regression Models for the Effects of Exposure Rate and Cumulative Exposure
David B Richardson (2012)
10.1186/1756-0500-5-482
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz (2011)
10.1016/J.EJCTS.2007.01.064
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
10.1016/j.cellsig.2010.10.003
Bone morphogenetic proteins: a critical review.
Beth Bragdon (2011)
10.1002/ijc.23609
Long‐term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
F. Barone-Adesi (2008)
10.1093/ANNHYG/46.SUPPL_1.90
Mortality in Miners and Millers of Crocidolite in Western Australia: Follow-up to 1999
A. Musk (2002)
10.1007/s12094-011-0617-x
Clinical-therapeutic management of thoracoscopy in pleural effusion: a groundbreaking technique in the twenty-first century
José Marcelo Galbis (2011)
10.1200/JCO.2015.33.15_SUPPL.7500
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.
Gérard Zalcman (2015)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1136/thx.2010.136978
Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010
C. Hooper (2010)
10.1016/j.jtcvs.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1038/sj.bjc.6601957
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
10.1016/j.bbcan.2014.01.008
The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma.
L. D. de Assis (2014)
10.1093/ACPROF:OSO/9780195149616.001.0001
Cancer epidemiology and prevention.
D. Schottenfeld (2006)
10.1521/psyc.2012.75.3.203
A Conceptual Framework for Understanding the Mental Health Impacts of Oil Spills: Lessons from the Exxon Valdez Oil Spill
L. Palinkas (2012)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1007/s11307-010-0426-6
Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment
Sandip Basu (2010)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
V. Rusch (1997)
10.1136/oem.53.12.813
Induction of mesothelioma after intrapleural inoculation of F344 rats with silicon carbide whiskers or continuous ceramic filaments.
N. B. Johnson (1996)
10.1016/S0720-048X(01)00426-0
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
Mechanisms of mineral fibre carcinogenesis.
A. Kane (1996)
10.1002/jcp.22724
Malignant mesothelioma: facts, myths, and hypotheses.
M. Carbone (2012)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1038/modpathol.2011.202
Mesotheliomas with small cell features: report of eight cases
N. Ordóñez (2012)
10.1097/JTO.0b013e31820ce2c7
Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma
Steven Kao (2011)
10.1634/theoncologist.2010-0185
What is the role of radiotherapy in malignant pleural mesothelioma?
Allan Price (2011)
10.1038/sj.bjc.6605848
SV40 associated miRNAs are not detectable in mesotheliomas
G. V. Gee (2010)
10.1097/RLI.0b013e3181817b3d
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
10.1259/bjr/55980445
Multidetector CT imaging of pleura: comparison of two contrast infusion protocols.
V. Raj (2011)
10.1158/1078-0432.CCR-11-2375
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
M. Ladanyi (2012)
10.1183/09031936.96.09122565
Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
C. J. Lindén (1996)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
10.1002/(SICI)1097-0274(199903)35:3<246::AID-AJIM4>3.0.CO;2-6
Latency analysis in epidemiologic studies of occupational exposures: application to the Colorado Plateau uranium miners cohort.
B. Langholz (1999)
Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
M. C. Franceschini (2014)
10.4329/wjr.v5.i10.372
Contrast-enhanced ultrasonography in peripheral lung consolidations: What's its actual role?
S. Sartori (2013)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1093/ANNHYG/44.8.565
The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure.
J. Hodgson (2000)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.3760/CMA.J.ISSN.0529-5807.2014.06.003
[Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases].
Iweng Lao (2014)
10.1093/AJE/KWI020
Research Methods in Occupational Epidemiology, Second Edition
H. Davies (2005)
10.1378/CHEST.129.6.1570
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
F. Giesel (2006)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
10.1289/ehp.1002845
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
10.1093/acprof:oso/9780195092424.001.0001
Research Methods in Occupational Epidemiology
H. Checkoway (1989)
10.1007/978-3-642-82218-6_8
Role of surgery.
N. Wright (1984)
10.1016/0013-9351(81)90143-2
Comparative pulmonary responses to inhaled inorganic fibers with asbestos and fiberglass.
K. P. Lee (1981)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1016/j.radonc.2011.09.025
Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series.
S. Tonoli (2011)
10.1016/S1010-7940(02)00735-2
The management of malignant pleural mesothelioma.
G. Maggi (2003)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1016/S0277-9536(02)00054-0
Impacts of an environmental disaster on psychosocial health and well-being in Karakalpakstan.
E. Crighton (2003)
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.1016/S0277-9536(01)00367-7
The social and psychological impact of the chemical contamination incident in Weston Village, UK: a qualitative analysis.
G. Barnes (2002)
10.1016/J.EJCTS.2003.12.001
The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma.
J. Pilling (2004)
10.1016/j.humpath.2012.05.014
Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.
N. Ordóñez (2013)
10.1093/annonc/mds535
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Zacariah E Labby (2013)
10.1016/S1010-7940(01)00995-2
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
A. Martin-Ucar (2001)
10.1016/S0360-3016(98)00409-X
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.
L. de Graaf-Strukowska (1999)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1080/10937404.2011.556051
Role of Mutagenicity in Asbestos Fiber-Induced Carcinogenicity and Other Diseases
Sarah X. L. Huang (2011)
10.1007/S11111-008-0075-8
Proximate industrial activity and psychological distress
J. Boardman (2008)
10.1093/ejcts/ezr251
The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.
A. Nakas (2012)
10.1016/J.ATHORACSUR.2004.01.034
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
D. Stewart (2004)
10.1016/J.CANRAD.2005.09.005
Progrès thérapeutiques récents dans le mésothéliome malin primitif de la plèvre
M. Mahé (2005)
10.1378/CHEST.120.6.1798
Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma.
R. F. Adams (2001)
10.1097/01.JTO.0000283221.63767.BA
C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma
H. Kindler (2007)
10.1016/j.mrfmmm.2011.01.001
XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
M. Betti (2011)
10.2214/ajr.154.3.2106209
CT in differential diagnosis of diffuse pleural disease.
A. Leung (1990)
10.1186/1476-069X-7-4
Translocation pathways for inhaled asbestos fibers
Giuseppe Miserocchi (2008)
10.1016/j.anndiagpath.2008.11.001
Surgery for malignant pleural mesothelioma.
David C. Rice (2009)
10.1016/J.LUNGCAN.2007.08.031
Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
A. Razak (2008)
10.1111/j.1752-699X.2011.00254.x
Outcomes and complications following medical thoracoscopy
F. Brims (2012)
10.2113/GSELEMENTS.3.6.407
Toxic Potential of Mineral Dusts
B. Fubini (2007)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1111/j.1365-2559.2008.03099.x
The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.
R. Attanoos (2008)
10.1007/978-3-642-10862-4_7
Surgical therapy of mesothelioma.
D. Rice (2011)
10.1378/CHEST.128.3.1431
Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.
S. Kolschmann (2005)
10.1093/aje/kwt273
Effect modification of the association of cumulative exposure and cancer risk by intensity of exposure and time since exposure cessation: a flexible method applied to cigarette smoking and lung cancer in the SYNERGY Study.
Jelle Vlaanderen (2014)
10.1111/j.1539-6924.2005.00643.x
Mesothelioma: Risk Apportionment Among Asbestos Exposure Sources
B. Price (2005)
10.1016/j.ccm.2006.02.001
Imaging of pleural disease.
N. R. Qureshi (2006)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1200/JCO.2011.38.5161
American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care.
T. Smith (2012)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes
Gusava
10.1093/ejcts/ezu001
Surgery for malignant pleural mesothelioma: why we need controlled trials.
Tom Treasure (2014)
10.1136/THX.2006.073080
Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic
W. Lim (2007)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Wieneke A. Buikhuisen (2013)
10.1097/SLA.0000000000000903
Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma: Novel Prognostic Implications of Combined N1 and N2 Nodal Involvement Based on Experience in 529 Patients
D. Sugarbaker (2014)
10.1002/dc.21380
Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions
S. Lonardi (2011)
10.1007/s11864-011-0154-4
Surgical Treatment of Malignant Pleural Mesothelioma
Andrew J. Kaufman (2011)
A rare occupation causing mesothelioma: mechanisms and differential etiology.
Giuseppe Mastrangelo (2014)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1093/aje/kwt274
Invited commentary: is it time to retire the "pack-years" variable? Maybe not!
D. Thomas (2014)
10.1158/1055-9965.EPI-05-0863
Cigarette Smoking and Lung Cancer: Modeling Total Exposure and Intensity
J. Lubin (2006)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
10.1378/CHEST.118.3.604
MRI and CT in the differential diagnosis of pleural disease.
J. Hierholzer (2000)
10.1002/dc.21398
Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations
K. Ikeda (2011)
10.1155/2014/413946
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
10.1371/journal.pone.0114483
Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
D. Weber (2014)
10.1093/ANNONC/MDU438.65
LBA37_PRNEOADJUVANT CHEMOTHERAPY AND EXTRAPLEURAL PNEUMONECTOMY (EPP) OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) WITH OR WITHOUT HEMITHORACIC RADIOTHERAPY: FINAL RESULTS OF THE RANDOMIZED MULTICENTER PHASE II TRIAL SAKK17/04
R. Stahel (2014)
10.1200/JCO.2010.28.15_SUPPL.7020
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.
Gérard Zalcman (2010)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1093/annonc/mdp318
European Society for Medical Oncology (ESMO) Program for the integration of oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program.
N. Cherny (2010)
10.1002/ajim.22063
Malignant mesothelioma incidence among talc miners and millers in New York State.
M. Finkelstein (2012)
10.1002/food.19760200233
WHO‐IARC‐Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. International Agency for Research on Cancer. Bd. 6 u. 7. Lyon 1974
W. Fritz (1976)
10.1111/j.1440-1673.1994.tb00177.x
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
S. Davis (1994)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1002/ijc.27758
Familial aggregation of malignant mesothelioma in former workers and residents of Wittenoom, Western Australia
N. de Klerk (2013)
10.3389/fpsyg.2014.01419
Helping traumatized people survive: a psychoanalytic intervention in a contaminated site
Fanny Guglielmucci (2014)
10.1038/bjc.2014.312
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
Giovanni Luca Ceresoli (2014)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
Giovanni Luca Ceresoli (2011)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1016/S0140-6736(03)13079-6
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial
N. Maskell (2003)
10.1289/ehp.10195
Cancer Mortality and Incidence of Mesothelioma in a Cohort of Wives of Asbestos Workers in Casale Monferrato, Italy
D. Ferrante (2007)
10.1093/toxsci/kfp100
Absence of carcinogenic response to multiwall carbon nanotubes in a 2-year bioassay in the peritoneal cavity of the rat.
J. Muller (2009)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1136/thoraxjnl-2014-206054
Role of CT in assessing pleural malignancy prior to thoracoscopy
R. J. Hallifax (2014)
10.1038/modpathol.2012.105
Deciduoid mesothelioma: report of 21 cases with review of the literature
N. Ordóñez (2012)
10.1002/gcc.22218
Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high‐risk area
M. Betti (2015)
10.1148/rg.346130089
Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.
Larry T Nickell (2014)
10.1016/j.canep.2014.02.014
Familial malignant mesothelioma: a population-based study in central Italy (1980-2012).
Valeria Ascoli (2014)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1177/002214650504600306
Environmental Stressors: The Mental Health Impacts of Living Near Industrial Activity∗
L. Downey (2005)
10.1016/S1470-2045(15)70056-2
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
10.1097/JTO.0000000000000499
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
N. Macleod (2015)
10.1016/J.MRREV.2007.08.001
Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor.
D. Ugolini (2008)
10.1080/028418501127347070
Evaluation of pleural disease using MR and CT: With special reference to malignant pleural mesothelioma
A. Knuuttila (2001)
10.1037/h0099382
The Deepwater Horizon Oil Spill and the Mississippi Gulf Coast: Mental health in the context of a technological disaster.
Christopher F. Drescher (2014)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.2131/JTS.34.65
Induction of mesothelioma by a single intrascrotal administration of multi-wall carbon nanotube in intact male Fischer 344 rats.
Y. Sakamoto (2009)
10.1016/j.ctrv.2012.11.004
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.
C. Pinto (2013)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1200/JCO.2007.25.18_SUPPL.18198
Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma
M. Serke (2007)
10.1136/oem.2003.008128
Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia
G. Berry (2004)
10.1016/S1556-0864(15)31536-7
Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma.
D. Sugarbaker (2006)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1097/MCP.0b013e3282fe9a04
Image-guided pleural biopsy
N. Rahman (2008)
10.1002/cncy.21342
The diagnosis of malignant mesothelioma in effusion cytology
A. Paintal (2013)
10.1002/cncr.23034
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
L. Greillier (2007)
10.1002/dc.23271
Guidelines for the cytopathologic diagnosis of epithelioid and mixed‐type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
A. Hjerpe (2015)
10.1038/bjc.1982.15
Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment.
J. Peto (1982)
10.1016/J.ATHORACSUR.2004.05.007
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
R. Bueno (2004)
10.1016/J.IJROBP.2005.03.041
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
V. Gupta (2005)
10.1002/sim.2783
Relative risk and acceleration in lung cancer.
Geoffrey Berry (2007)
AIOM documento di consenso sulle cure simultanee at www.aiom.it
N Cherny (2010)
10.1038/sj.bjc.6601638
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
10.1002/cncy.21392
Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
V. Jo (2014)
10.1007/s11864-014-0314-4
Local and Systemic Therapies for Malignant Pleural Mesothelioma
D. Gomez (2014)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.1093/ACPROF:OSO/9780195149616.003.0034
Pleural and Peritoneal Neoplasms
P. Boffetta (2009)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.2217/LMT.14.17
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
Giovanni Luca Ceresoli (2014)
10.1016/j.athoracsur.2014.09.056
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
Emanuela Taioli (2015)
10.1097/01.PAT.0000454221.37254.a1
Diagnosis of mesothelioma by cytology using Japanese criteria
Toshiaki Kawai (2014)
10.1037/0003-066X.48.6.665
Implications of psychological research on stress and technological accidents.
A. Baum (1993)
10.1016/J.LUNGCAN.2005.12.013
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
G. Oxnard (2006)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
10.1038/modpathol.2012.39
Pleomorphic mesothelioma: report of 10 cases
N. Ordóñez (2012)
10.1038/modpathol.2012.172
Mesothelioma with signet-ring cell features: report of 23 cases
N. Ordóñez (2013)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
CT and MR imaging in the evaluation of pleural masses.
Heelan Rt (1994)
10.2105/AJPH.2010.300039
Community stress, psychosocial hazards, and EPA decision-making in communities impacted by chronic technological disasters.
Stephen R. Couch (2011)
Economic burden of Mesothelioma in Italy. Communication at International Conference on Monitoring and Surveillance of Asbestos‐related diseases
S Iavicoli (2014)
10.2131/JTS.33.105
Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube.
A. Takagi (2008)
10.1016/S0140-6736(65)91824-6
AGE AT ONSET OF LUNG CANCER: SIGNIFICANCE IN RELATION TO EFFECT OF SMOKING.
M. Pike (1965)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1038/nnano.2008.111
Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study.
Craig A. Poland (2008)
10.1002/AJIM.20451
Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature.
V. Ascoli (2007)
10.1510/icvts.2010.255893
What is the best way to diagnose and stage malignant pleural mesothelioma?
I. Zahid (2011)
10.1634/theoncologist.2014-0312
Integration of oncology and palliative care: a systematic review.
D. Hui (2015)
10.1002/ijc.20820
Predictions of mortality from pleural mesothelioma in Italy: A model based on asbestos consumption figures supports results from age‐period‐cohort models
A. Marinaccio (2005)
10.1016/j.mrrev.2008.02.002
Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases.
M. Neri (2008)
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
V. Ambrosini (2005)
10.1200/JCO.2009.25.9275
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
10.1378/chest.09-0884
Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
Muzaffer Metintas (2010)
10.1093/annonc/mdv101
Searching for targets for the systemic therapy of mesothelioma.
Rolf Arno Stahel (2015)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1016/j.rmed.2009.05.017
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
10.1378/chest.107.5.1454
Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.
D. Waller (1995)
10.1007/s10552-009-9328-9
Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005
S. Moolgavkar (2009)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1093/annonc/mdp271
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
A. Avigdor (2010)
10.1111/j.1349-7006.2012.02223.x
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshie Yoshikawa (2012)
10.1080/10937404.2011.556049
Non-Neoplastic and Neoplastic Pleural Endpoints Following Fiber Exposure
V. Broaddus (2011)
10.1002/ijc.22592
Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples
Kristina Kjærheim (2007)
10.1200/JCO.2009.26.9944
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
P. Wheatley-Price (2010)
10.1097/JTO.0b013e3181b9eb85
Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques
Christine E Hill-Kayser (2009)
10.1053/j.semtcvs.2009.06.011
Current trends in radiologic management of malignant pleural mesothelioma.
Ritu R Gill (2009)
10.1097/JTO.0b013e31828354c8
Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma
Zacariah E Labby (2013)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1378/chest.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.4103/0019-5278.43261
Susceptibility and resistance in the genesis of asbestos-related mesothelioma
C. Bianchi (2008)
10.2147/NDT.S48965
Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers
A. Granieri (2013)
10.1016/J.RADONC.2006.06.002
The role of radiation therapy in malignant pleural mesothelioma: a systematic review.
Y. Ung (2006)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
10.1016/J.THORSURG.2004.06.006
Patterns of failure following surgical resection for malignant pleural mesothelioma.
P. Jänne (2004)
10.1016/S0936-6555(05)80582-5
The role of palliative radiotherapy in malignant mesothelioma.
D. Bissett (1991)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/S0954-6111(98)90100-7
Medical thoracoscopy, results and complications in 146 patients: a retrospective study.
M. Hansen (1998)
10.1158/1078-0432.CCR-07-5283
Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma
K. Tournoy (2008)
10.1016/S1470-2045(05)70471-X
Survival from rare cancer in adults: a population-based study.
G. Gatta (2006)
10.1378/chest.103.4_Supplement.382S
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
V. Rusch (1993)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1016/j.athoracsur.2005.06.014
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Pathology and genetics of tumours of the lung , pleura, thymus and heart
W. D. Travis (2004)
10.1136/jcp.48.7.691-a
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
A. Zuckerman (2010)
10.3109/08958370903521224
Refractory ceramic fiber (RCF) toxicity and epidemiology: A review
Mark J. Utell (2010)
10.3816/CLC.2010.n.048
Individualizing mesothelioma treatment: small steps into a brighter future.
Linda L. Garland (2010)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1053/j.ro.2013.03.017
Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.
M. Truong (2013)
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1378/CHEST.125.2.489
Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
B. Duysinx (2004)
10.1016/j.ijrobp.2014.08.343
Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.
W. W. Chance (2015)
10.1016/j.athoracsur.2009.05.022
Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.
D. Rice (2009)
10.1007/s10552-009-9357-4
Ionizing radiation: a risk factor for mesothelioma
J. Goodman (2009)
10.1016/j.jtcvs.2008.12.045
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
Tristan D. Yan (2009)
10.1146/ANNUREV.PUBLHEALTH.28.021406.144123
Risk communication for public health emergencies.
D. Glik (2007)
10.1016/J.EJCTS.2005.10.008
Multimodality approach in management of malignant pleural mesothelioma.
S. Neragi-Miandoab (2006)
10.1510/icvts.2009.213611
Staging algorithm for diffuse malignant pleural mesothelioma.
M. Zieliński (2010)
10.1016/j.lungcan.2013.10.013
Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
E. Minatel (2014)
10.1159/000377697
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma
A. Hjerpe (2015)
10.1200/jco.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1016/J.EJCTS.2007.09.039
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
A. Nakas (2008)
10.1097/PAS.0b013e3182910c82
Diffuse Intrapulmonary Malignant Mesothelioma Masquerading as Interstitial Lung Disease: A Distinctive Variant of Mesothelioma
B. Larsen (2013)
10.1016/j.cancergen.2013.05.018
Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.
M. Cheung (2013)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.1289/ehp.1002915
The Early Psychological Impacts of the Deepwater Horizon Oil Spill on Florida and Alabama Communities
L. Grattan (2011)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
Research Methods in Occupational Epidemiology, Second Edition
H. Checkoway (2005)
10.1249/01.MSS.0000257790.26527.CE
Cancer Epidemiology and Prevention, 3rd Edition
S. Gapstur (2007)
10.1196/ANNALS.1371.042
The economic costs of health service treatments for asbestos-related mesothelioma deaths.
A. Watterson (2006)
10.5858/arpa.2010-0604-RA
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
P. Betta (2012)
10.2486/INDHEALTH.39.168
A trial on the quantitative risk assessment of man-made mineral fibers by the rat intraperitoneal administration assay using the JFM standard fibrous samples.
S. Adachi (2001)
10.1043/0003-9985(1999)123<0039:PFTEOS>2.0.CO;2
Protocol for the examination of specimens from patients with malignant pleural mesothelioma: a basis for checklists. Cancer Committee, College of American Pathologists.
G. Nash (1999)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)



This paper is referenced by
10.1007/978-3-319-31215-6_22-1
Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer
Massimo Di Maio (2017)
10.1186/s12940-019-0510-6
Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy
F. Luberto (2019)
10.3389/fpsyg.2018.00205
“The Less I Think About It, the Better I Feel”: A Thematic Analysis of the Subjective Experience of Malignant Mesothelioma Patients and Their Caregivers
Fanny Guglielmucci (2018)
10.21037/jtd.2017.10.74
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
Luca Ampollini (2018)
10.1016/j.biopha.2017.01.118
Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
F. Petrella (2017)
10.1016/j.canlet.2017.06.028
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
M. Betti (2017)
10.1016/j.prp.2016.07.010
Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
Valeria Ascoli (2016)
10.15167/2421-4248/jpmh2019.60.4.1330
Health impact of exposure to asbestos in polluted area of Southern Italy
L. Vimercati (2019)
10.1016/j.rmed.2018.06.026
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
Fausto Petrelli (2018)
10.1016/j.canlet.2016.05.011
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
M. Betti (2016)
10.1155/2018/2438598
Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization
Annalisa Bosi (2018)
10.1093/carcin/bgv097
Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
S. Tunesi (2015)
10.23750/abm.v88i2.5558
Diagnostic imaging and workup of malignant pleural mesothelioma
Luciano Cardinale (2017)
10.3390/ijerph17020607
Predictions of Mortality from Pleural Mesothelioma in Italy After the Ban of Asbestos Use
E. Oddone (2020)
10.1002/9781119023647.CH8
Children's and Adult Involuntary and Occupational Exposures and Cancer
Annamaria Colacci (2017)
10.21037/jtd.2017.10.125
The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.
G. Alí (2018)
10.1097/JOM.0000000000001211
Asbestos Exposures, Mesothelioma Incidence and Mortality, and Awareness by General Practitioners in the Molise Region, Central Italy
Giancarlo Ripabelli (2018)
10.3390/cancers11060831
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma
A. Catino (2019)
10.1016/j.critrevonc.2016.08.011
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
G. Bronte (2016)
10.1002/dc.24395
Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.
Sulaf Abd Own (2020)
10.1111/1759-7714.13456
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study
A. Trama (2020)
10.1007/s00280-014-2477-x
High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin
Ó. Arrieta (2014)
10.23749/mdl.v109i2.5865
Mortality in a cohort of asbestos-exposed workers undergoing health surveillance.
Fabiano Barbiero (2018)
10.1002/ajim.22831
The psychological distress and care needs of mesothelioma patients and asbestos‐exposed subjects: A systematic review of published studies
Michela Bonafede (2018)
10.4103/0366-6999.196585
Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment
Cheng-jun Ban (2017)
10.4415/ANN_18_02_10
Mesothelioma in Italy: the Casale Monferrato model to a national epidemiological surveillance system.
P. Comba (2018)
10.1177/0300891618820007
On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016).
Pietro Gino Barbieri (2018)
10.3978/j.issn.2072-1439.2013.08.08
Malignant pleural mesothelioma: current and future perspectives.
Konstantinos Porpodis (2013)
10.5301/tj.5000593
Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care)
V. Zagonel (2017)
10.1539/joh.16-2003-LT
Comments on the causation of malignant mesothelioma: rebutting the false concept that recent exposures to asbestos do not contribute to causation of mesothelioma
Collegium Ramazzini (2016)
10.1136/oemed-2015-102803
Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment
D. Ferrante (2015)
10.1016/j.biopha.2018.09.040
Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines.
I. Rimoldi (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar